Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.